[Life-threatening hyperuricemia during cytostatic leukemia therapy].
In 25 children with lymphoblastic leukemia is shown that prophylactic treatment with allopurinol, 48 hours before initial cytostatic therapy, always prevents hyperuricemia. In 4 patients was renounced on this measurement and 2 of 4 patients died of the sequeles of hyperuricemia. In severe ill leukemic patients the parental use of allopurinol is recommended. 2 additional patients developed during remission therapy or after cessation of chemotherapy a moderate hyperuricemia which had to be treated, over years, with allopurinol.
D000293:Adolescent; D000493:Allopurinol / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D010419:Pentamidine / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000188:drug therapy; D014527:Uric Acid / Q000097:blood*; D014750:Vincristine / Q000627:therapeutic use
D014527:Uric Acid; D014750:Vincristine; D000493:Allopurinol; D010419:Pentamidine; D001215:Asparaginase; D008775:Methylprednisolone
Lebensbedrohliche Hyperurikämie bei zytostatischer Leukämie-Therapie.